The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.
about
The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The EGFR tyrosine kinase inhib ...... in People's Republic of China.
@en
The EGFR tyrosine kinase inhib ...... in People's Republic of China.
@nl
type
label
The EGFR tyrosine kinase inhib ...... in People's Republic of China.
@en
The EGFR tyrosine kinase inhib ...... in People's Republic of China.
@nl
prefLabel
The EGFR tyrosine kinase inhib ...... in People's Republic of China.
@en
The EGFR tyrosine kinase inhib ...... in People's Republic of China.
@nl
P2093
P2860
P356
P1476
The EGFR tyrosine kinase inhib ...... in People's Republic of China.
@en
P2093
Baohui Han
Guozheng Ding
Huiming Wang
Jianlin Xu
Xueyan Zhang
Yanwei Zhang
Yuqing Lou
P2860
P304
P356
10.2147/OTT.S119341
P407
P577
2016-10-20T00:00:00Z